These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms today.If you are looking to day trade, you might want to check out the following stocks. I usually throw these on my watch list and monitor with resistance & support levels.You can also check previous stocks to buy reports- Right Here.
Neurocrine Biosciences (NBIX), TD Ameritrade (AMTD, Morgan Stanley (MS) , BlackRock (BLK), Par Pharmaceutical (PRX) and Triple-S (GTS) were upgraded or downgraded by analysts.
Neurocrine Biosciences (NBIX), TD Ameritrade (AMTD, Morgan Stanley (MS) , BlackRock (BLK), Par Pharmaceutical (PRX) and Triple-S (GTS) were upgraded or downgraded by analysts.
Neurocrine Biosciences (NBIX) initiated with a Buy at Deutsche Bank.Target $15.
TD Ameritrade (AMTD) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded TD Ameritrade citing valuation and a mixed macro outlook. The firm raised its price target for shares to $20 from $18.
Morgan Stanley (MS) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded Morgan Stanley citing valuation and a mixed macro outlook. The firm lowered its price target for shares to $22 from $28.
BlackRock (BLK) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded BlackRock citing valuation and a mixed macro outlook. The firm keeps a $210 price target for shares.
Par Pharmaceutical (PRX) initiated with a Neutral at JPMorgan.Target $40.
Triple-S (GTS) downgraded to Market Perform from Outperform at Wells Fargo.Wells Fargo downgraded Triple-S citing valuation and decreasing Medicare Advantage rates in Puerto ico. The firm lowered its price target range for shares to $22-$24 from $25-$28.
TD Ameritrade (AMTD) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded TD Ameritrade citing valuation and a mixed macro outlook. The firm raised its price target for shares to $20 from $18.
Morgan Stanley (MS) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded Morgan Stanley citing valuation and a mixed macro outlook. The firm lowered its price target for shares to $22 from $28.
BlackRock (BLK) downgraded to Hold from Buy at Deutsche Bank.Deutsche Bank downgraded BlackRock citing valuation and a mixed macro outlook. The firm keeps a $210 price target for shares.
Par Pharmaceutical (PRX) initiated with a Neutral at JPMorgan.Target $40.
Triple-S (GTS) downgraded to Market Perform from Outperform at Wells Fargo.Wells Fargo downgraded Triple-S citing valuation and decreasing Medicare Advantage rates in Puerto ico. The firm lowered its price target range for shares to $22-$24 from $25-$28.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
